Dr Ranjan Pai has joined its Board of Directors and Dr Richard Buchta has joined Vyome as Senior Vice-President of R&D
Vyome Biosciences announced that MD and CEO of Manipal Education and Medical Group, Dr Ranjan Pai, has joined its Board of Directors. Pai’s venture firm Aarin Capital is an investor in Vyome. Dr Richard Buchta, formerly Head of GlaxoSmithKline’s dermatology unit Stiefel Laboratories in Australia, has joined Vyome as Senior Vice-President of R&D.
Pai is recognised as one of India’s top corporate leaders. As Vyome scales operations and prepares to enter the commercialisation phase, his addition adds tremendous strategic experience to the Board. The globalisation and expansion of the Manipal Education and Medical Group through his strategic vision is an experience that will serve Vyome in good stead as the company looks abroad for development and licensing opportunities, said N Venkat, Co-founder and CEO.
“Vyome is a proving to be a serious innovative play in the life sciences industry, and holds a special place in Aarin’s portfolio. I am personally looking forward to work more closely with the rest of the board, Shiladitya, Venkat and the rest of their team as the company breaks new ground in markets both in India and abroad,” said Dr Ranjan Pai, Chairman of Manipal Education & Medical Group and Founding Partner at Aarin Capital.
Dr Buchta brings rich specialist experience with numerous patent applications and multiple IND filings in dermatology to Vyome’s senior management team, and this will multiply the company’s capabilities as we enter the regulatory filing stages for our pharmaceutical programmes.
EP News Bureau – Mumbai